Table 3.
Predictive value of pre-therapy MAA imaging for estimating TD and NTWLD (using Bland–Altman analyses for measuring the extremes).
| Studies | Type of Microspheres | Post Therapy Imaging | Type of Tumors | Nb of Patients | Nb of Tumors | TD Estimation (Relative 95% CI) + |
NTWLD Estimation (Relative 95% CI) + |
|---|---|---|---|---|---|---|---|
| Kafrouni et al. 2019 [36] | glass | 90Y PET/CT | HCC | 23 | 24 | −29%; +29% | −34%; +34% |
| Richetta et al. 2019 [32] | resin | 90Y PET/CT | HCC | 10 | 10 | −39%; +33% | −24%; +31% |
| Jafargholi Rangraz et al. 2020 [33] | resin | 90Y PET/CT | HCC and mets | 31 | 67 | −169%; +146% | −30%, +23% |
| Jadoul et al. 2020 [42] |
resin and glass | 90Y PET/CT | HCC and mets | 57 | 137 | −100%; +100% | −36%, +36% |
| d’Abadie et al. 2021 [34] | resin | 90Y PET/CT | HCC and mets | 66 | 171 | −76%; +320% | −19%, +24% |
HCC: hepatocellular carcinoma; mets: metastases; TD: Tumor absorbed dose; Nb: number; NTWLD: non-tumoral whole liver absorbed dose; + In some studies, absolute 95% CI were converted in relative 95% CI (comparison to the mean).